Inovio Closes Enrollment in Brain Cancer Study Before Time

Inovio Pharmaceuticals, Inc. INO announced that it has completed enrolling patients in the phase I/II study on its immuno-oncology combo of INO-5401 plus INO-9012 in combination with Regeneron REGN/Sanofi’s SNY PD-1 inhibitor, Libtayo (cemiplimab), for treating the newly-diagnosed patients with glioblastoma (GBM).